CPT Code: 83704
Order Code: 37847
Includes: LDL Particle Number (LDL-P), Small LDL Particle Number (Small LDL-P), LDL Size, HDL Particle Number (HDL-P), Large HDL Particle Number (Large HDL-P), HDL Size, Large VLDL Particle Number (Large VLDL-P), VLDL Size
ABN Requirement: No
Specimen: Serum
Volume: 2.0 mL
Minimum Volume: 1.0 mL
Container: Red Top (no gel barrier) tube
Collection:
-
- Gently invert draw tube 5X (DO NOT SHAKE).
- Let blood clot for 30-60 minutes at room temperature.
- Centrifuge for 10 minutes.
- Aliquot top layer from red-top draw tube and place SERUM in transport tube and dispose of draw tube. Label the transport tube as “No Additive Serum Red”. ONLY ship No Additive Serum in transport tube.
- Store and transport refrigerated. Specimen is stable at -20° for 10 days and -70° for 28 days but CANNOT BE SHIPPED ON DRY ICE.
Fasting: Patient should be fasting 12 hours.
Transport: Store serum at 2°C to 8°C after collection and ship the same day per packaging instructions included with the provided shipping box.
Stability:
Ambient (15-25°C): Unacceptable
Refrigerated (2-8°C): 7 days
Frozen (-20°C): Unacceptable
Deep Frozen (-70°C): Unacceptable
Causes for Rejection: Gross hemolysis; Grossly lipemic; Serum separator tube (SST); Sample received on dry ice
Methodology: Nuclear Magnetic Resonance (NMR)
Turn Around Time: 3 days
Relative Risk Range:
| Test | Reference Range | Low | Relative Risk Range Moderate | High |
|---|---|---|---|---|
| LDL-P (nmol/L) | 592-2404 | <935 | 935-1816 | >1816 |
| Small LDL-P (nmol/L) | <1408 | <467 | 467-820 | >820 |
| LDL Size (nm) | 20.0-22.3 | >20.5 | N/A | ≤20.5 |
| HDL-P (µmol/L) | 21.1-43.4 | >32.8 | 29.2-32.8 | <29.2 |
| Large HDL-P (µmol/L) | >3.5 | >7.2 | 5.3-7.2 | <5.3 |
| HDL Size (nm) | 8.3-10.5 | >9.0 | 8.7-9.0 | <8.7 |
| Large VLDL-P (nmol/L) | <16.0 | <3.7 | 3.7-6.1 | >6.1 |
| VLDL Size (nm) | 41.1-61.7 | <47.1 | 47.1-49.0 | >49.0 |
Clinical Significance: The Lipoprotein Fractionation NMR test is used to help assess the risk for cardiovascular disease (CVD) in patients with intermediate or high risk based on traditional or emerging risk factors, and to assess therapeutic response in patients undergoing lipid-lowering therapy, by quantification of the number and size of lipoprotein particles.
The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.